Urea Cycle Disorder - Symptoms, Causes, Treatment & Prevention

Overview

Urea cycle disorders (UCDs) are a group of rare, inherited metabolic conditions in which the body cannot properly convert ammonia—a toxic by‑product of protein metabolism—into urea for excretion. When the cycle breaks down, ammonia accumulates in the bloodstream, leading to neurological dysfunction that can be life‑threatening if not treated promptly.

Who it affects: UCDs are autosomal recessive or X‑linked disorders, so they can affect both males and females, although X‑linked forms (e.g., ornithine transcarbamylase deficiency) are more common in males. The overall prevalence of all UCDs combined is estimated at 1 in 35,000 live births, making them one of the more common groups of inborn errors of metabolism [1].

The age of presentation varies widely. Some infants develop severe symptoms within the first days of life, while others (especially those with partial enzyme deficiencies) may not be diagnosed until childhood, adolescence, or even adulthood after a metabolic stressor such as infection, surgery, or a high‑protein diet.

Symptoms

Symptoms result from elevated ammonia and may affect the brain, liver, and other organ systems. They can be acute (rapid onset) or chronic (recurrent, milder). Below is a comprehensive list:

Neurological symptoms

• Encephalopathy: confusion, irritability, lethargy, or coma.
• Seizures: can be focal or generalized.
• Ataxia: loss of coordination and balance.
• Developmental delay: especially in children diagnosed after infancy.
• Behavioral changes: hyperactivity, poor attention, or mood swings.
• Hypotonia: decreased muscle tone.

Gastrointestinal symptoms

• Nausea or vomiting (often the first sign in infants).
• Loss of appetite.
• Failure to thrive or poor weight gain in infants.

Other systemic symptoms

• Respiratory alkalosis (low CO₂) due to hyperventilation.
• Hepatomegaly (enlarged liver) in some forms.
• Excessive sleepiness after meals (post‑prandial lethargy).

Because symptoms can mimic many other conditions (e.g., meningitis, sepsis, or liver disease), a high index of suspicion is essential, especially in newborns with unexplained vomiting or poor feeding.

Causes and Risk Factors

UCDs are caused by mutations in any of the eight genes that encode enzymes or transport proteins of the urea cycle. The most common forms include:

• Ornithine transcarbamylase (OTC) deficiency – X‑linked (≈ 1/14,000 male births) [2]
• Carbamoyl‑phosphate synthetase I (CPS1) deficiency
• Argininosuccinate synthetase (ASS1) deficiency – also called citrullinemia type I
• Argininosuccinate lyase (ASL) deficiency – also called argininosuccinic aciduria
• Arginase 1 deficiency
• N‑acetylglutamate synthase (NAGS) deficiency
• Transporter defects (e.g., citrin deficiency)

Risk factors

• Family history: Parents who are carriers of a pathogenic variant have a 25% chance per pregnancy of having an affected child (autosomal recessive) or a 50% chance for sons in X‑linked OTC deficiency.
• Consanguinity: Increased risk in populations where close relatives intermarry.
• Metabolic stressors: In individuals with partial enzyme activity, infections, surgery, trauma, fasting, or high protein intake can precipitate a crisis.

Diagnosis

Timely diagnosis is crucial because untreated hyperammonemia can cause irreversible brain injury.

Newborn screening

Many countries include selected UCDs (OTC, CPS1, citrullinemia) in their routine heel‑stick newborn screen. Elevated concentrations of amino acids such as citrulline, arginine, or glutamine may trigger further testing.

Biochemical testing

• Plasma ammonia: A level > 100 µmol/L in a newborn or > 150 µmol/L in an older child is abnormal and warrants urgent evaluation.
• Plasma amino acids (via tandem mass spectrometry): Patterns of elevated or decreased specific amino acids help pinpoint the defective enzyme.
• Urine organic acids: May reveal characteristic metabolites (e.g., orotic acid in OTC deficiency).
• Blood gas analysis: Often shows respiratory alkalosis.

Genetic testing

Sequencing of the relevant genes confirms the diagnosis, guides prognosis, and enables carrier testing and prenatal diagnosis. Whole‑exome or targeted gene panels are now standard in most referral centers.

Imaging

Brain MRI may be performed after a crisis to assess for cerebral edema or permanent injury, but it is not diagnostic for UCD itself.

Treatment Options

Treatment aims to reduce ammonia, prevent its buildup, and address the underlying enzymatic defect.

Acute management (medical emergencies)

1. Rapid ammonia reduction: Intravenous nitrogen scavengers such as sodium phenylacetate/sodium benzoate (often combined as Ammonul®) bind ammonia for renal excretion.
2. Hemodialysis or continuous renal replacement therapy (CRRT): Used when ammonia > 300 µmol/L or when medical therapy fails.
3. Calorie and protein restriction: Provide high‑calorie, low‑protein intravenous dextrose to prevent catabolism.
4. L‑arginine supplementation: Supplies a downstream substrate to promote waste nitrogen excretion (except in arginine‑deficiency disorders).

Long‑term maintenance

• Dietary management: A lifelong low‑protein diet tailored by a metabolic dietitian; specialized medical foods (e.g., amino‑acid–free formulas) are often required.
• Oral nitrogen scavengers: Sodium phenylbutyrate (Buphenyl®) or glycerol phenylbutyrate (Ravicti®) are taken daily to provide an alternative pathway for ammonia removal.
• L‑citrulline or L‑arginine supplementation: Depending on the specific enzyme defect, these can improve the urea cycle flux.
• Liver transplantation: Curative for many severe UCDs, especially OTC deficiency and CPS1 deficiency; success rates exceed 85% 5‑year survival [3].

Emerging therapies

• Gene therapy: Early‑phase trials using adeno‑associated virus (AAV) vectors for OTC deficiency have shown promising reductions in ammonia levels [4].
• mRNA therapy: Investigational approaches delivering functional enzyme mRNA are under evaluation.

Living with Urea Cycle Disorder

With appropriate treatment, most individuals lead active, productive lives, but daily vigilance is required.

Nutrition & Meal Planning

• Work with a registered metabolic dietitian to calculate individual protein allowances (often 0.6–1.0 g/kg/day).
• Use specialized medical formulas at each meal to meet caloric needs without excess protein.
• Never skip meals; regular carbohydrate intake helps prevent catabolism.

Medication Adherence

• Take nitrogen scavengers exactly as prescribed; missed doses can cause rapid ammonia rise.
• Carry a medication list and emergency contact card at all times.

Monitoring

• Routine plasma ammonia checks every 3–6 months (or more often if symptomatic).
• Annual liver function tests and growth tracking in children.
• Use home ammonia monitoring kits only under physician guidance; they are not a substitute for lab tests.

Lifestyle & Activities

• Avoid fasting; eat small, frequent meals, especially before exercise or illness.
• Stay hydrated; dehydration can precipitate a crisis.
• Promptly treat infections with antibiotics and increase caloric intake.
• Inform school staff, coaches, and employers about the condition and emergency plan.

Psychosocial Support

Living with a chronic metabolic disease can be stressful. Counseling, support groups (e.g., United Metabolic Disease Foundation), and educational resources help patients and families cope.

Prevention

Because UCDs are genetic, primary prevention focuses on carrier identification and family planning.

• Carrier screening: Available for OTC, CPS1, and other UCD genes; recommended for couples with a family history or those from high‑risk ethnic groups.
• Prenatal diagnosis: Chorionic villus sampling or amniocentesis with targeted genetic testing can determine if a fetus is affected.
• Pre‑implantation genetic testing (PGT‑M): Allows selection of embryos without the pathogenic variant during in‑vitro fertilization.
• Newborn screening: Early detection through state‑mandated programs reduces mortality and improves outcomes.

Complications

If hyperammonemia is not controlled, serious complications may develop.

• Neurologic injury: Cerebral edema, seizures, permanent cognitive deficits, or developmental disability.
• Recurrent metabolic crises: Can lead to school or work absenteeism and decreased quality of life.
• Liver dysfunction: Chronic overload may cause fibrosis in some patients.
• Growth failure: Inadequate nutrition and repeated crises can stunt height and weight gain.
• Psychiatric disorders: Mood swings, anxiety, or attention‑deficit disorders are reported in adolescents and adults.

When to Seek Emergency Care

References

1. Mayo Clinic. “Urea cycle disorders.” Updated 2023. https://www.mayoclinic.org/diseases-conditions/urea-cycle-disorders
2. National Organization for Rare Disorders (NORD). “Ornithine Transcarbamylase (OTC) Deficiency.” 2022.
3. American Liver Foundation. “Liver Transplantation for Metabolic Diseases.” 2021.
4. Wang, B. et al. “AAV‑mediated Gene Therapy for Ornithine Transcarbamylase Deficiency—Preclinical and Early Clinical Results.” *Molecular Therapy*, 2023.
5. Cleveland Clinic. “Urea Cycle Disorders – Management Overview.” 2024.